Newark, DE, United States of America

Paul John Krenitsky

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignee: Dupont Pharmaceuticals Company. Active years: 2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul John Krenitsky. Retrieved from https://idiyas.com/inventor/paul-john-krenitsky

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 86(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Paul John Krenitsky: Innovator in Cystic Fibrosis Treatment

Introduction

Paul John Krenitsky is a notable inventor in the field of pharmaceutical sciences, particularly recognized for his contributions to the treatment of cystic fibrosis. His innovative work focuses on the modulation of the cystic fibrosis transmembrane conductance regulator, which is crucial for developing effective therapies for this genetic disorder.

Latest Patents

Although Paul John Krenitsky currently holds no patents, his significant work includes the development of a modulator of the cystic fibrosis transmembrane conductance regulator. This invention encompasses pharmaceutical compositions, methods of treatment, and processes for making the modulator. The compounds disclosed include those of Formula (I), pharmaceutically acceptable salts, deuterated derivatives, and metabolites, which are essential for advancing cystic fibrosis treatment.

Career Highlights

Krenitsky is associated with Vertex Pharmaceuticals, Inc., a leading biotechnology company that focuses on developing innovative medicines for serious diseases. His role at Vertex has allowed him to contribute to groundbreaking research and development efforts aimed at improving the lives of patients with cystic fibrosis.

Collaborations

Throughout his career, Paul John Krenitsky has likely collaborated with various researchers and professionals in the pharmaceutical industry. These collaborations are vital for fostering innovation and advancing the development of effective treatments for cystic fibrosis and other related conditions.

Conclusion

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…